Regulatory Breakthrough: CDSCO Greenlights Leiutis Pharma’s Synthetic CBD Solution for Anxiety Treatment

Regulatory Breakthrough: CDSCO Greenlights Leiutis Pharma’s Synthetic CBD Solution for Anxiety Treatment​

The Central Drugs Standard Control Organisation (CDSCO) has officially granted approval to Zenara Pharma for the manufacture of a synthetic cannabidiol oral solution. This new treatment is specifically designed to manage mild to moderate anxiety disorders.

This regulatory milestone marks a significant development in the pharmaceutical landscape, providing a new therapeutic pathway for patients. The medication is intended to be administered alongside cognitive behavioural therapy to ensure comprehensive patient care.

Clinical Validation and Prescription Guidelines​

The approved 150 mg/mL prescription medicine is restricted for use only under the supervision of psychiatrists. This strict oversight ensures that the treatment remains within professional medical parameters for anxiety management.

Authority figures, including Leiutis Pharma Founder K Chandrasekhar, underscored the importance of the product's synthetic origin. He noted that because the product is fully synthetic, it is non-psychotropic and contains no cannabis plant material.

The approval was secured following a rigorous India-based Phase III clinical trial. During this testing phase, the treatment demonstrated statistically significant efficacy when compared against a placebo while maintaining a satisfactory safety profile.

Strategic Development and Technological Integration​

The production of this innovative treatment involved a multi-party collaborative effort to ensure high-quality pharmaceutical standards. Biophore was responsible for developing the synthetic CBD API, which serves as the core active ingredient.

Complementing this research, Leiutis Pharmaceuticals provided the critical nano-dispersible drug-delivery technology. This synergy between chemical development and delivery science is expected to enhance the efficacy of the oral solution.

Zenara Pharma will handle the manufacturing responsibilities for the product. The company will utilize its established production facilities which currently hold approvals from India, the USFDA, and the EU.

Next Steps in Clinical Evaluation​

While Phase III trials have provided a foundation of safety and efficacy, the regulatory journey continues with further testing. Zenara Pharma is scheduled to conduct a Phase IV trial to compare the synthetic CBD medicine against the existing standard of care.

This data will be vital for establishing the medication's role in the current treatment landscape. The move toward large-scale manufacturing and comparative testing positions Leiutis and Zenara at the forefront of cannabinoid-based pharmaceutical innovation in India.